Brief: Immuneering Announces Positive Topline Results From Phase 1 Portion Of Imm-1-104 In Ras-Mutant Solid Tumors

Immuneering

14/03/2024 12:06

March 14 (Reuters) - Immuneering Corp  IMRX.O :
    * IMMUNEERING ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE
1
PORTION OF ITS PHASE 1/2A CLINICAL TRIAL OF IMM-1-104 IN
RAS-MUTANT SOLID TUMORS
    * IMM-1-104 HAS BEEN WELL-TOLERATED, DEMONSTRATING POTENTIAL
FOR A
DIFFERENTIATED SAFETY PROFILE
    * IMM-1-104 HAS BEEN WELL-TOLERATED, DEMONSTRATING POTENTIAL
FOR A
DIFFERENTIATED SAFETY PROFILE
    * INITIAL DATA FROM MULTIPLE ARMS OF PHASE 2A PORTION OF
IMMUNEERING'S PHASE 1/2A STUDY OF IMM-1-104 EXPECTED IN 2024
    * FIRST PATIENT IN PHASE 1/2A TRIAL OF IMM-6-415 EXPECTED TO
BE
DOSED IN MARCH 2024

Source text for Eikon:  ID:nGNX5XL8lM 
Further company coverage:  IMRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))